Year: 2023

Lilium has opened private sales of its eVTOL jets in the U.S. marketLilium Pioneer Edition Jet flying over DallasTexas-based EMCJET, responding to premium market interest, secures production slots for the first U.S. Lilium Pioneer Edition Jets Marks the first time Lilium Jets, or any eVTOL aircraft, will be available for private purchase in the U.S. market Initial sales focus will be on customers in key Texas cities including Austin, Houston, San Antonio, and DallasHOUSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) — Lilium N.V. (NASDAQ: LILM), developer of the first all-electric vertical take-off and landing (“eVTOL”) jet, has today opened private sales of its eVTOL jets in the U.S. market, in partnership with EMCJET, an industry-leading full-service aircraft brokerage and management company. EMCJET is set to be the exclusive...

– Company to Host Conference Call and Webcast on November 8, 2023, at 8:00 a.m. ET SHANGHAI, China and CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the third quarter of 2023 and recent corporate updates, after the closing of the U.S. equity markets on November 7, 2023. The Company will host a live conference call and webcast on November 8, 2023, at 8:00 a.m. ET. Conference Call and Webcast Information Listeners may access the live webcast by visiting the Company’s website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows: Registration Link: https://register.vevent.com/register/BI87a7a83f6a6441279fddbaae217dd092 All participants must use the link...

WARMINSTER, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following investor conference: H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference: Formal Presentation on October 25, 2023 at 4:30 pm ET To access the live webcast of the presentation please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a limited time after the event. About Arbutus Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage...

Figure 1Figure 1: Soil Sampling Results from Camp and River Zones at the Mallard Gold ProjectTORONTO, Oct. 18, 2023 (GLOBE NEWSWIRE) — Platinex Inc. (CSE: PTX) (OTCQB: PANXF, Frankfurt: 9PX) (“Platinex” or the “Company”) is pleased to provide an update on exploration activities at the Mallard Gold (“Mallard”) and Heenan Gold (“Heenan”) projects located in northeastern Ontario which are, along with the Shining Tree Gold Project, held through the South Timmins Mining Joint Venture (“South Timmins JV”) with Fancamp Exploration Limited.Exploration activity at Mallard has identified surface gold mineralization approximately 500 m southeast of the Camp and River Zones indicating a potential expansion of these zones. Grab samples collected from the new area show up to 0.98 g/t Au and soil samples trend up to 1,210 ppb Au (1.21...

NTLA-2001 is the first-ever investigational in vivo CRISPR-based gene editing therapy cleared to enter late-stage clinical developmentCAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy. The global Phase 3 study of NTLA-2001, an in vivo CRISPR-based gene editing candidate, is expected to initiate by year-end 2023. “The FDA clearance of the NTLA-2001 IND application allows us to initiate a pivotal Phase 3 trial in the United States,...

ROAD TOWN, British Virgin Islands, Oct. 18, 2023 (GLOBE NEWSWIRE) — Aura Minerals Inc. (TSX: ORA, B3: AURA33 and OTCQX: ORAAF) (“Aura” or the “Company”) is pleased to announce that it has implemented a gold hedging program for the Borborema Project (“Hedging Program”), to de-risk and secure the return on capital invested during the first three years of production at Borborema. Highlights of the Hedging Program:Aura has hedged about 215,000 ounces of gold between July 2025 to June 2028 (the “Period”) using gold-collars established with several financial institutions. The derivatives were booked at Aura’s corporate level, and the total volume is not projected to exceed about 20% of Aura’s expected consolidated gold production for the Period, significantly decreasing the risk of potential over-hedging. Aura purchased put options...

U.S. Food and Drug Administration grants temporary discretion to import critical Erythromycin ophthalmic ointment for treatment of newborns BOUCHERVILLE, Québec, Oct. 18, 2023 (GLOBE NEWSWIRE) — LSL Pharma Group Inc. (TSXV: LSL), (the “Company” or “LSL Pharma Group”), a Canadian integrated pharmaceutical company, announced today that it has entered into an exclusive agreement with Fera Pharmaceuticals, LLC (“Fera”), a U.S. specialty pharmaceutical company, to provide Erythromycin ophthalmic ointment USP (5mg/g) for the treatment of newborns in U.S. hospitals. Given the scarcity of Erythromycin ophthalmic ointment south of the border, the U.S. Food and Drug Administration (“FDA”) granted Fera temporary discretion to import this vital medication used in the prevention of gonococcal ophthalmia neonatorum. The agreement essentially...

WAUKESHA, Wis., Oct. 18, 2023 (GLOBE NEWSWIRE) — Generac Holdings Inc. (“Generac”) (NYSE: GNRC), a leading global designer and manufacturer of energy technology solutions and other power products, today announced plans to release its third quarter 2023 financial results before the market opens on Wednesday, November 1, 2023. Generac management will hold a conference call at 10:00 a.m. EDT on that day to discuss highlights of this earnings release. The conference call can be accessed at the following link: https://register.vevent.com/register/BIa6e8539444e2408eb5d52b8ff3526ea5. Individuals that wish to listen via telephone will be given dial-in information. The conference call will also be webcast simultaneously on Generac’s website (http://www.generac.com), under the Investor Relations link. The webcast link will be...